EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction

Ixchel Lima-Posada iD, Yohan Stephan iD, Matthieu Soulié iD, Roberto Palacios-Ramirez iD, Benjamin Bonnard iD, Lionel Nicol iD, Peter Kolkhof iD, Frederic Jaisser, Paul Mulder

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24032536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ixchel Lima-Posada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, UMRS 1138, INSERM, Sorbonne Université, Université Paris Cité, 75006 Paris, France. Hauptthemen laut MEDLINE: Heart Failure, Metabolic Syndrome, Renal Insufficiency, Chronic, Heart Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by grants from the Institut National de la Santé et de la Recherche Médicale, the ANR NGAL-HT, Fondation de France and a research gran…, Institut National de la Santé et de la Recherche Médicale, Fondation de France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mineralocorticoid receptor (MR) plays an important role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Antagonizing the overactivation of the MR with MR antagonists (MRA) is a therapeutic option, but their use in patients with CKD is limited due to the associated risk of hyperkalemia. Finerenone is a non-steroidal MRA associated with an improved benefit-risk profile in comparison to steroidal MRAs. In this study, we decided to test whether finerenone improves renal and cardiac function in male hypertensive and diabetic ZSF1 rats as an established preclinical HFpEF model. Finerenone was administered at 10 mg/kg/day for 12 weeks. Cardiac function/hemodynamics were assessed in vivo. ZSF1 rats showed classical signs of CKD with increased BUN, UACR, hypertrophy, and fibrosis of the kidney together with characteristic signs of HFpEF including cardiac fibrosis, diastolic dysfunction, and decreased cardiac perfusion. Finerenone treatment did not impact kidney function but reduced renal hypertrophy and cardiac fibrosis. Interestingly, finerenone ameliorated diastolic dysfunction and cardiac perfusion in ZSF1 rats. In summary, we show for the first time that non-steroidal MR antagonism by finerenone attenuates cardiac diastolic dysfunction and improves cardiac perfusion in a preclinical HFpEF model. These cardiac benefits were found to be largely independent of renal benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureMetabolic SyndromeRenal Insufficiency, ChronicHeart DiseasesMaleRatsAnimalsMineralocorticoid Receptor AntagonistsStroke VolumeNaphthyridinesFibrosisHypertrophyReceptors, Mineralocorticoid

Stichwörter der Autor:innen

diabetesdiastolic dysfunctionfinerenoneheart failuremineralocorticoid receptor antagonist

Substanzen

Mineralocorticoid Receptor AntagonistsfinerenoneNaphthyridinesReceptors, Mineralocorticoid

Autor:innen und Institutionen

  • Centre de Recherche des Cordeliers, UMRS 1138, INSERM, Sorbonne Université, Université Paris Cité, 75006 Paris, France.
  • INSERM EnVI UMR 1096, Univ Rouen Normandie, 76183 Rouen, France.
  • Cardiovascular Precision Medicines, Research and Early Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany.
  • INSERM, Clinical Investigation Centre 1433, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT (Cardiovascular and Renal Clinical Trialists), 54500 Nancy, France.

ORCID-Profile: Ixchel Lima-Posada, Yohan Stephan, Matthieu Soulié, Roberto Palacios-Ramirez, Benjamin Bonnard, Lionel Nicol, Peter Kolkhof

Förderung

  • This research was funded by grants from the Institut National de la Santé et de la Recherche Médicale, the ANR NGAL-HT, Fondation de France and a research gran…
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation de France
  • Bayer-AG

Zitieren

APA

Lima-Posada, I., Stephan, Y., Soulié, M., Palacios-Ramirez, R., Bonnard, B., Nicol, L., Kolkhof, P., Jaisser, F., & Mulder, P. (2023). Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032536

Vancouver

Lima-Posada I, Stephan Y, Soulié M, Palacios-Ramirez R, Bonnard B, Nicol L, et al. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032536

BibTeX
@article{LimaPosada2023,
  author = {Lima-Posada, Ixchel and Stephan, Yohan and Soulié, Matthieu and Palacios-Ramirez, Roberto and Bonnard, Benjamin and Nicol, Lionel and Kolkhof, Peter and Jaisser, Frederic and Mulder, Paul},
  title = {Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24032536}
}
Kostenlos starten →